Soleno Therapeutics, Inc.SLNONASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +66.70% | +27.54% | +30.68% | +27.34% | +21.06% |
| Weighted Average Shares Diluted Growth | +66.70% | +27.54% | +30.68% | +31.14% | +23.69% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +83.17% | +88.40% | +9.26% | +102.18% | +70.36% |
| Book Value per Share Growth | -6.64% | +27.01% | -34.55% | +46.80% | +51.69% |
| Debt Growth | +13008.19% | +15114.41% | +17727.36% | -7.26% | -94.91% |
| R&D Expense Growth | +147.28% | -7.43% | -25.89% | -72.11% | -55.52% |
| SG&A Expenses Growth | +801.04% | +245.36% | +171.65% | -31.39% | +9.58% |